1
|
Boucherle B, Bertrand J, Maurin B, Renard BL, Fortuné A, Tremblier B, Becq F, Norez C, Décout JL. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo. Eur J Med Chem 2014; 83:455-65. [PMID: 24992073 DOI: 10.1016/j.ejmech.2014.06.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Revised: 06/12/2014] [Accepted: 06/13/2014] [Indexed: 01/28/2023]
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) is the main chloride channel present in the apical membrane of epithelial cells and the F508 deletion (F508del-CFTR) in the CF gene is the most common cystic fibrosis-causing mutation. In the search for a pharmacotherapy of cystic fibrosis caused by the F508del-CFTR, a bi-therapy could be developed associating a corrector of F508del-CFTR trafficking and an activator of the channel activity of CFTR. Here, we report on the synthesis of 9-alkyladenine derivatives analogues of our previously discovered activator of wt-CFTR and F508del-CFTR, GPact-11a, and the identification of a new activator of these channels, GPact-26a, through various flux assays on human airway epithelial CF and non-CF cell lines and in vivo measurement of rat salivary secretion. This study reveals that the possible modifications of the side chain introduced at the N9 position of the main pharmacophore are highly limited since only an allyl group can replace the propyl side chain present in GPact-11a to lead to a strong activation of wt-CFTR in CHO cells. Docking simulations of the synthesised compounds and of four described modulators performed using a 3D model of the wt-type CFTR protein suggest five possible binding sites located at the interface of the nucleotide binding domains NBD1/NBD2. However, the docking study did not allow the differentiation between active and non-active compounds.
Collapse
Affiliation(s)
- Benjamin Boucherle
- Université Grenoble Alpes, Joseph Fourier/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, 470 rue de la Chimie, F-38041 Grenoble, France
| | - Johanna Bertrand
- Université de Poitiers/CNRS, Laboratoire Signalisation et Transports Ioniques Membranaires, 1 rue Georges Bonnet, F-86022 Poitiers, France
| | - Bruno Maurin
- Université Grenoble Alpes, Joseph Fourier/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, 470 rue de la Chimie, F-38041 Grenoble, France
| | - Brice-Loïc Renard
- Université Grenoble Alpes, Joseph Fourier/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, 470 rue de la Chimie, F-38041 Grenoble, France
| | - Antoine Fortuné
- Université Grenoble Alpes, Joseph Fourier/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, 470 rue de la Chimie, F-38041 Grenoble, France
| | - Brice Tremblier
- Université de Poitiers/CNRS, Laboratoire Signalisation et Transports Ioniques Membranaires, 1 rue Georges Bonnet, F-86022 Poitiers, France
| | - Frédéric Becq
- Université de Poitiers/CNRS, Laboratoire Signalisation et Transports Ioniques Membranaires, 1 rue Georges Bonnet, F-86022 Poitiers, France
| | - Caroline Norez
- Université de Poitiers/CNRS, Laboratoire Signalisation et Transports Ioniques Membranaires, 1 rue Georges Bonnet, F-86022 Poitiers, France
| | - Jean-Luc Décout
- Université Grenoble Alpes, Joseph Fourier/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, 470 rue de la Chimie, F-38041 Grenoble, France.
| |
Collapse
|